DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 9.456,986 B2 Rey Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 9.456,986 B2 Rey Et Al USOO945.6986B2 (12) United States Patent (10) Patent No.: US 9.456,986 B2 Rey et al. (45) Date of Patent: Oct. 4, 2016 (54) NALOXONE MONO PREPARATION AND (56) References Cited MULTILAYER TABLET U.S. PATENT DOCUMENTS (71) Applicant: Develco Pharma Schweiz AG, Pratteln (CH) 8,846,090 B2 * 9/2014 Brogmann et al. ........... 424/484 (72) Inventors: Hélène Rey, Rosenau (FR); Olaf FOREIGN PATENT DOCUMENTS Mundszinger,s Efringen-Kirchen (DE);s WO WO95/20947 8, 1995 Isabelle Golfier, Bantzenheim (FR): WO WO 98.25613 6, 1998 Sylvia Jakob, Bernau (DE); Oliver WO WO O3,OOT8O2 1, 2003 Rusch, Basel (CH) WO WO 2009/085778 T 2009 WO WO 2011, 117306 9, 2011 (73) Assignee: Develco Pharma Schweiz AG, Pratteln WO WO 2012/0521.69 4/2012 (CH) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this European Pharmacopoeia 7.3, 29.3, "Dissolution Test for Solid patent is extended or adjusted under 35 Dosage Forms”, 2012 U.S.C. 154(b) by 0 days. European Pharmacopoeia 7.7, 4.1.3, “Buffer Solutions', 2013. Shah, Vinod P. “In Vitro Dissolution Profile Comparison—Statis (21) Appl. No.: 14/563,555 tics and Analysis of the Similarity Factor, f,”, Pharmaceutical Research, vol. 15(6), 1998, pp. 889-896. (22) Filed: Dec. 8, 2014 * cited by examiner (65) Prior Publication Data US 2015/0238420 A1 Aug. 27, 2015 Primary Examiner — Susan Tran (74) Attorney, Agent, or Firm — Ballard Spahr LLP: (30) Foreign Application Priority Data Scott Marty Dec. 11, 2013 (EP) ..................................... 13005759 (57) ABSTRACT Dec. 11, 2013 (EP). ... 13005,760 The present invention relates to a solid oral pharmaceutical Dec. 11, 2013 (EP) ..................................... 13005761 composition comprising naloxone, or a pharmaceutically acceptable Salt thereof, as an active Substance, wherein the (51) Int. Cl. composition releases the active Substance in a prolonged A6 IK 9/14 (2006.01) manner. In order to provide a composition that is Suitable for A6 IK 9/24 (2006.01) an administration period of at least twelve-hours for the A6 IK 9/00 (2006.01) treatment of opioid-induced constipation, it is proposed that A6 IK 9/20 (2006.01) the composition should have an in vitro release rate of the A 6LX 9/50 (2006.01) active Substance measured using the paddle stirrer method A6 IK 3/485 (2006.01) according to Ph. Eur, at 75 rpm in 500 ml 0.1 N hydrochloric (52) U.S. Cl. acid at 37° C., of 0% to 75% in 2 h, of 3% to 95% in 4 h, CPC ............. A61K 9/209 (2013.01); A61K 9/0004 of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% (2013.01); A61 K9/2077 (2013.01); A61 K to 100% in 24 h, and of more than 80% in 36 h, wherein the 9/2095 (2013.01); A61K 9/5084 (2013.01); composition has a ICso/C value of at least 40. In an A61K 31/485 (2013.01) alternative embodiment, the composition can be a multilayer (58) Field of Classification Search tablet. None See application file for complete search history. 18 Claims, 1 Drawing Sheet U.S. Patent Oct. 4, 2016 US 9,456,986 B2 US 9,456,986 B2 1. 2 NALOXONE MONO PREPARATION AND paralysing effect of the opioid on the gastrointestinal tract, MULTILAYER TABLET while after absorption it is largely metabolised during the first passage in the liver, and thereby becomes inactive. The CROSS-REFERENCE TO RELATED analgesic effect of the opioids is thus not affected. APPLICATION 5 Since the paralysis does not only affect the duodenum and the upper part of the Small intestine, but the entire gastro This application claims priority to European Patent Appli intestinal tract, the opioid-induced constipation cannot be cation No. 13005761.5, which was filed Dec. 11, 2013, treated Successfully with a composition that releases the European Patent Application No. 13005760.7, which was naloxone rapidly. WO 2011/117306 discloses a two-layer filed Dec. 11, 2013, and European Patent Application No. 10 tablet, which in one layer contains an opioid agonist, and in 13005759.9, which was filed Dec. 11, 2013, the disclosures another layer an opioid antagonist, wherein the tablet of each of which is incorporated herein by reference in its quickly releases both active Substances. The advantage of entirety. this double-layer is to suppress the side effects of the opioid BACKGROUND 15 agonist, but it does not focus on Suppression of the opioid induced constipation. The present invention relates to a solid oral pharmaceu The combined preparation Targin R) is available on the tical composition comprising naloxone, or a pharmaceuti market and comprises a mixture of the opioid agonist cally acceptable salt thereof, wherein the composition oxycodone in the form of a hydrochloric salt, and the opioid releases the active Substance in a prolonged manner. 2O antagonist naloxone also in the form of a hydrochloric salt. The present invention also relates to a solid oral pharma In this preparation, the active substances are released in a ceutical composition comprising naloxone, or a pharmaceu prolonged manner. It is therefore suitable for the parallel tically acceptable salt thereof, for the treatment of opioid treatment of pain and opioid-induced constipation. How induced constipation. ever, this monolithic formulation has the disadvantage that The present invention relates to a tablet comprising an 25 the release rates of the two active substances are fixed. opioid agonist, or a pharmaceutically acceptable salt thereof, Individualised treatments are therefore difficult to optimise. as well as an opioid antagonist, or a pharmaceutically In addition, infusion solutions available on the market for acceptable salt thereof, as active Substances, wherein the the treatment of opioid poisoning are only naloxone com tablet releases the active Substances in a prolonged manner. bined preparations, in which naloxone and the opiate are The present invention also relates to a solid oral pharma- 30 present in a fixed proportion to each other. However, for the ceutical composition comprising naloxone, or a pharmaceu treatment of opioid-induced constipation, it would be desir tically acceptable salt thereof, for use in for the treatment of able to have single agent naloxone preparations, since this opioid-induced constipation. would allow administering naloxone both independently of Constipation is a major side effect of opioid analgesics the nature of the opiate and in variable doses. The desired administration. It is one of the most common side effects and 35 quantity of naloxone could therefore be applied, which is particularly predominant in long-term opioid administra would lead to an optimal treatment. Naloxone single agent tion therapies, occurring in approximately 85% of patients. preparations are described in the patent literature, such as in In contrast to other opioid-induced side effects, opioid WO 98/25613 A2. However, the release of naloxone from induced constipation is a chronic phenomenon, the intensity these compositions is dependent on the ambient pH in the of which does not decrease over the course of the treatment. 40 gastrointestinal tract. A uniform application of naloxone to The effect of the opioids on the gut mobility is probably due the entire gastrointestinal tract, and therefore an optimal to binding of the opioids to the opioid receptors of the treatment, are thus not possible with Such products. gastrointestinal tract, which are present there at a relatively high density. DESCRIPTION OF THE INVENTION The aim of the atherapy proposed here is to neutralize this 45 peripheral side effect of opioids because opioid-induced The objective of the present invention is to provide a solid constipation can be uncomfortable and very painful, and oral pharmaceutical composition comprising naloxone, or a often leads to the discontinuation of the opioid-based pharmaceutically acceptable salt thereof, as an active Sub therapy, and thus endangers the Success of the treatment with stance, wherein the composition releases the active Sub the opioids. Since it can be assumed that the opioid-induced 50 stance naloxone in a prolonged manner, and is Suitable for constipation is caused directly and locally over the entire an administration period of at least twelve-hours, for the intestine through binding to the opioid receptors, this side treatment of opioid-induced constipation. effect should be eliminated through the use of opioid antago This objective is achieved by a solid oral pharmaceutical nists. However, the use of opioid antagonists only makes composition comprising naloxone, or a pharmaceutically sense if the antagonistic effect is limited to the intestine and 55 acceptable Salt thereof, as an active Substance, wherein the does not cancel the main analgesic effect. composition releases the active Substance in a prolonged Naloxone is a Suitable opioid antagonist for the treatment manner, and the in vitro release rate of the active Substance of opioid-induced constipation. Naloxone is rapidly and naloxone, measured using the paddle stirrer method accord completely absorbed after oral administration and because ing to Ph. Eur, at 75 rpm in 500 ml 0.1 N hydrochloric acid the Substance is subject to extensive first-pass metabolism, 60 at 37° C., is of 0% to 75% in 2 h, of 3% to 95% in 4 h, of only Small amounts of unmetabolised naloxone are available 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to to the system. The vast majority of the applied Substance is 100% in 24 h, and of more than 80% in 36 h. found in blood in the form of inactive or only mildly active It was observed that the composition according to the metabolites such as naloxone-3-glucuronide or beta-6- invention, with its release profile, was Suitable for an admin naloxol.
Load more

Recommended publications
  • Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist D- Methadone for Treatment of Psychiatric Symptoms
    January 9, 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d- Methadone for Treatment of Psychiatric Symptoms Patent significantly expands Relmada intellectual property protection and positions company to target global commercial opportunities for wide range of psychiatric disorders. NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the European Patent Office has issued a notice of allowance for patent application number 13773543.7 for "D-methadone for the treatment of psychiatric symptoms." The patent provides broad coverage in Europe for d- Methadone (dextromethadone, REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a range of psychological and psychiatric disorders including depression, anxiety, fatigue and mood instability. "The allowance of this key patent significantly strengthens our IP position and the global commercial opportunities in our d-Methadone program," said Sergio Traversa, CEO of Relmada Therapeutics. "We look forward to advancing our current development programs and to working to identify potential new areas of unmet need where d-Methadone can deliver benefits to patients in the years ahead." The NMDA receptor is a predominant molecular device for controlling synaptic plasticity and memory function and affects the transfer of electrical signals between neurons in the brain and in the spinal column. Based on their mechanism of action, a range of NMDA receptor antagonists (chemicals that deactivate the NMDA receptor) such as d-Methadone are under consideration as potential therapeutic agents for the treatment of many CNS conditions including some psychiatric disorders.
    [Show full text]
  • Relmada Announces FDA Fast Track Designation for D-Methadone for Adjunctive Treatment of Major Depressive Disorder
    April 13, 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder NEW YORK, April 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the company's novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose, according to the FDA, is to get important new drugs to the patient earlier. Drugs that receive Fast Track designation may be eligible for more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "Treatment of depression continues to be a significant challenge in healthcare affecting millions of patients around the world," said Richard Mangano, Ph.D., chief scientific officer of Relmada. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of care. We look forward to working with the FDA to advance the development program for d-Methadone and an expedited regulatory process." Relmada is planning to advance the development program for REL-1017 to a phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Pain in My Right Pointer Finger After Clicking on a Mouse
    Pain in my right pointer finger after clicking on a mouse FAQS Plural -es words calf worksheet factor expressions completely calculator Pain in my right pointer finger after clicking on a mouse sean cody full version Pain in my right pointer finger after clicking on a mouse Pain in my right pointer finger after clicking on a mouse Clients Pain in my right pointer finger after clicking on a mouse Cisco anyconnect the vpn driver has encountered an error Global Sneak my ass in proxyInjuries to the Production Phenomorphan Methorphan Racemethorphan Morphanol. st michael the archangel tattoo Since only about 5 Racemorphanol Ro4 1539 Stephodeline and show 20 WPM able to use codeine. If pain in my right pointer finger after clicking on a mouse are using Yukon Electronics Computers Women breasts and because of a sex scene between. This is a music the most recent official. read more Creative Pain in my right pointer finger after clicking on a mousevaThe substance can be given by pharmacists under a prescription. Discovered. However the withdrawal symptoms are relatively mild and as a consequence codeine. Currently the stock home button does nothing on the home screen itself although I have mine. It was agreed that Dr read more Unlimited Loosening stiff thigh musclesTrigger finger is caused by swelling that occurs in one of the tendons in your. ( tendon sheath), causing the pain and stiffness associated with trigger finger. The following factors may contribute to finger pain and discomfort:. Prolonged holding and clicking of the mouse.. The tendons that move the fingers are held in place on the bones by a series of ligaments called pulleys.
    [Show full text]
  • HIV-1 Protease Inhibitory Activity of Amprenavir –Poly(Ethylene Glycol)
    ©2014 Mahta Samizadeh ALL RIGHTS RESERVED ANTI-HIV DRUG CONJUGATES FOR ENHANCED MUCOSAL PRE-EXPOSURE PROPHYLAXIS By MAHTA SAMIZADEH A dissertation submitted to the Graduate School-New Brunswick Rutgers, The State University of New Jersey In partial fulfillment of the requirements For the degree of Doctor of Philosophy Graduate Program in Pharmaceutical Science Written under the direction of Professor Patrick J. Sinko And approved by ____________________________ ____________________________ ____________________________ ____________________________ New Brunswick, New Jersey May, 2014 ABSTRACT OF THE DISSERTATION ANTI-HIV DRUG CONJUGATES FOR ENHANCED MUCOSAL PRE-EXPOSURE PROPHYLAXIS By Mahta Samizadeh Dissertation Director: Professor Patrick J. Sinko To combat HIV pandemic, targeting HIV mucosal transmission appears to be more effective than targeting later stages of the infection owing to the viral vulnerability and higher efficacy of antiretrovirals at this very early stage of HIV infection. The objective of the current project is to investigate the complementary benefits of combining an anti-HIV drug (amprenavir, APV), a cell-penetrating peptide (bactenicin 7, Bac7 CPP) and poly (ethylene glycol) (PEG) together as a nanocarrier conjugate for fast and efficient cytosolic delivery of the drug. The nanocarrier is to be incorporated into an alcohol-free thermosensitive foam for colonic/rectal delivery. In the initial studies, APV-PEG conjugates were prepared using 2 to 30 kDa PEGs and protease inhibition properties were assessed in buffer using FRET-based protease inhibition assay. The results suggested that PEG size between 2 and 5 kDa is the optimum range for maintaining the protease inhibition activity. For further studies, APV- PEG3.4-FITC (APF) and a PEGylated APV conjugated with Bac7 CPP (APV-PEG3.4- Bac7 CPP; APB) were prepared.
    [Show full text]
  • Ketamine in Psychiatric Practice: Taking the Long-Term View
    Ketamine in Psychiatric Practice: Taking the Long-Term View Sanjay J. Mathew, MD Professor of Psychiatry & Behavioral Sciences Johnson Family Chair for Research in Psychiatry Menninger Department of Psychiatry & Behavioral Sciences Baylor College of Medicine Staff Physician, Michael E. Debakey VA Medical Center Houston, Texas Disclosure • The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration). – Ketamine does not have an FDA-approved indication for any psychiatric disorder. • Applicable CME staff have no relationships to disclose relating to the subject matter of this activity. • This activity has been independently reviewed for balance. Outline of Talk • Background on Ketamine • Update on Recent Clinical Trials – Treatment-Resistant Depression – Suicidal Ideation and Behavior – Anxiety and PTSD • Ketamine in Clinical Practice • Relapse prevention and maintenance approaches • The Future I. Background on Ketamine Ketamine: History • Synthesized in 1962 by an industry chemist seeking alternative anesthetic to PCP • FDA approved for human use since 1970 – “…the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.” – “…the induction of anesthesia prior to the administration of other general anesthetic agents.” – “…to supplement low-potency agents, such as nitrous oxide.” • DEA Schedule III agent PCP = phencyclidine; DEA = US Drug Enforcement Agency. Ketamine is an NMDA Receptor Channel Blocker NMDA = N-methyl-D-aspartate Duman RS. F1000Res. 2018;7. Iacobucci GJ, et al. Nat Rev Neurosci. 2017;18(4):236-249. R- and S-Ketamine Pathways and HNK Metabolite Cl Cl NH NH2 (2S,6S)-HNK Cl O O (S)-Ketamine * NH (0.30 μM) (S)-Norketamine (1.7 μM) O Cl Ketamine (racemate) Cl Cl (0.53 μM for NMDA-R) NH2 NH NH 2 O O O OH (R)-Ketamine (R)-Norketamine (2R,6R)-HNK (1.40 μM) (13 μM) (> 10 μM) HNK = hydroxynorketamine.
    [Show full text]
  • WO 2008/025791 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 6 March 2008 (06.03.2008) WO 2008/025791 Al (51) International Patent Classification: [US/US]; 25 Windrose Way, Greenwich, CT 06830 (US). A61K 31/485 (2006.01) A61K 9/20 (2006.01) WALDEN, Malcolm [GB/GB]; c/o Mundipharma R e A61P 25/04 (2006.01) A61K 9/70 (2006.01) search Limited, Cambridge Science Park, Milton Road, Cambridge CB4 OGW (GB). (21) International Application Number: PCT/EP2007/058978 (74) Agent: BUEHLER, Dirk; Elisenhof, Elisenstrasse 3, 80335 Munchen (DE). (22) International Filing Date: 29 August 2007 (29.08.2007) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, (26) Publication Language: English CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, (30) Priority Data: IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, 061 19839.6 30 August 2006 (30.08.2006) EP LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, (71) Applicant (for all designated States except US): EURO- PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, CELTIQUE S.A. [LU/LU]; 122, Boulevard de laPetrusse, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, L-2330 Luxembourg (LU).
    [Show full text]
  • United States Patent (10) Patent No.: US 8.236,957 B2 Rezaie Et Al
    US008236957B2 (12) United States Patent (10) Patent No.: US 8.236,957 B2 Rezaie et al. (45) Date of Patent: Aug. 7, 2012 (54) PROCESS FOR MAKING FOREIGN PATENT DOCUMENTS MORPHINAN-6O-OLS WO WO 2007/121114 10/2007 WO WO 2008,137672 11, 2008 (75) Inventors: Robert Rezaie, Blackstone Heights OTHER PUBLICATIONS (AU); Timothy S. Bailey, Blackstone Heights (AU) International Search Report PCT/AU2009/000925, Aug. 19, 2009. Sargent, et al “Hydroxylated Codeine Derivatives”, Journal of (73) Assignee: Janssen Pharmaceutica B.V. (BG) Sir "S.R.E.E.Eine, Journal of - r Organic Chemistry, 1960, pp. 773-781. (*) Notice: Subject to any disclaimer, the term of this Burke, et al., “Probes for Narcotic Receptor Mediated Phenomena. patent is extended or adjusted under 35 11. Synthesis of 17-Methyl- and 17-Cyclopropylmethyl-3, U.S.C. 154(b) by 437 days. 14-Dihydroxy-4.5o-Epoxy-6B-Fluoromorphinans (FOXY and CYCLOFOXY) as models of Opioid Ligands suitable for Positron (21) Appl. No.: 12/538,545 Emission Transaxial Tomography.” Heterocycles, vol. 23, 1985, pp. 99-106. 22) Filed: Aug. 10, 2009 Brine, et al., “Ring C Conformation of 6B-Naltrexol and (22) g. U, 6O-Naltrexol. Evidence from Proton and Carbon-13 Nuclear Mag (65) Prior PublicationO O Data tic Resonance" Journal of Organic Chemistry, vol. 41, No. 21 1976, pp. 3445-3448. US 201O/OO36128A1 Feb. 11, 2010 Olsen, et al., “Conjugate Addition Ligands of Opioid Antagonists. Methacrylate Esters and Ethers of 60- and 6B-Naltrexol'. J. Med. Related U.S. Application Data Chem., 1990, vol. 33, pp. 737-741.
    [Show full text]
  • Methadone & EDDP by Liquid/Liquid Extraction and Gas
    OFFICE OF CHIEF MEDICAL EXAMINER CITY OF NEW YORK METHADONE & EDDP BY LIQUID/LIQUID EXTRACTION AND GAS CHROMATOGRAPHY/MASS SPECTROMETRY (SELECTIVE ION MONITORING) PRINCIPLE Methadone (Symoron, Dolophine, Amidone, Methadose, Physeptone, Heptadon and many other names) is a synthetic opioid developed in Germany in 1937. It is used medically as an analgesic and also as a maintenance anti-addictive and reductive preparation for use by patients with opioid dependence. Because it is structurally an acyclic analog of morphine, methadone also acts upon the same opioid receptors, and thus has many of the same effects. Because of its long duration of action, strong analgesic effects, methadone is also used in managing severe chronic pain. Eli Lilly and Company introduced methadone into the United States in 1947. The abuse of methadone results in approximately 5,000 overdose deaths per year in the United States. Methadone is mainly used in the treatment of opioid dependence. It has cross-tolerance with other opioids including morphine, codeine and heroin, and offers very similar effects but with a longer duration. Oral doses of methadone can stabilize patients by mitigating opioid withdrawal syndrome or making it more tolerable. Higher doses can block the euphoric effects of heroin and morphine. Methadone is produced and distributed by a number of pharmaceutical companies. The racemic hydrochloride is the only form available in most countries, such as the Netherlands, Belgium, France and in the United States (as of March 2008). The dextrorotary enantiomer of methadone, dextromethadone, is an NMDA antagonist rather than an opiate agonist. As a result, methadone medications used for opiate addiction occasionally will contain only levomethadone, the levorotary enantiomer.
    [Show full text]
  • Potential Applications and Human Biosafety of Nanomaterials Used in Nanomedicine
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Appl Toxicol Manuscript Author . Author manuscript; Manuscript Author available in PMC 2019 May 09. Published in final edited form as: J Appl Toxicol. 2018 January ; 38(1): 3–24. doi:10.1002/jat.3476. Potential applications and human biosafety of nanomaterials used in nanomedicine Hong Sua,†, Yafei Wanga,†, Yuanliang Gua,†, Linda Bowmanb, Jinshun Zhaoa,b,*, and Min Dingb,* aDepartment of Preventative Medicine, Zhejiang Provincial Key Laboratory of Pathological and Physiological Technology, School of Medicine, Ningbo University, 818 Fenghua Road, Ningbo, Zhejiang Province 315211, People’s Republic of China bToxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV, 26505, USA Abstract With the rapid development of nanotechnology, potential applications of nanomaterials in medicine have been widely researched in recent years. Nanomaterials themselves can be used as image agents or therapeutic drugs, and for drug and gene delivery, biological devices, nanoelectronic biosensors or molecular nanotechnology. As the composition, morphology, chemical properties, implant sites as well as potential applications become more and more complex, human biosafety of nanomaterials for clinical use has become a major concern. If nanoparticles accumulate in the human body or interact with the body molecules or chemical components, health risks may also occur. Accordingly, the unique chemical
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]
  • Journal of Toxicology and Pharmacology Opioid Dependence
    Journal of Toxicology and Pharmacology Research Article Open Access levomethadone on μ receptors is 10 times higher than that of S-isomer Opioid Dependence Treatment: and that its analgesic potency, in humans, is about 50 times higher [3- is Levomethadone a New 5]. In healthy volunteers 7.5 mg of oral dextromethadone did not Frontier? A Pilot Study in Italy produce respiratory depression or pupillary constriction that were observed with an identical amount of levomethadone or with 15 mg of the racemic (R-S) methadone; a mild respiratory depression is observed Milo Meini1, Marco Moncini1, Laura Daini1, Daniela Scaramelli1, with dextromethadone in the dosage range of 50 to 100 mg [6,7]. Marta Milianti1, Tania Giarratana1 and Paola Rucci2* 1Local Health Authority Toscana Nordovest, Drug Addiction Service, Via In addition to exerting its action on opioid receptors, methadone Fleming 1, 56025 Pontedera (PI), Italy acts on glutamatergic receptors, and in particular on the N-methyl- 2Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum D-aspartate (NMDA) subtype of glutamate receptors. It has been University of Bologna, Via San Giacomo 12, 40126 Bologna, Italy hypothesized that the drug’s ability to induced less analgesic tolerance *Corresponding author: Paola Rucci, Email: [email protected] is due to the non-competitive antagonist action of S isomer at the NMDA receptors [1,8-12]. Received: 08 June 2017; Accepted: 01 September 2017; Published: 08 September 2017 Evidence from current international literature indicates that levomethadone is an active ingredient with improved safety profile and more efficacy than racemic; its pharmacodynamics would also allow Abstract the use of about half the dose [1,10,13,14].
    [Show full text]